UK markets closed

Ion Beam Applications SA (IOBCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
13.900.00 (0.00%)
As of 09:30AM EDT. Market open.

Ion Beam Applications SA

3, Chemin du Cyclotron
Louvain-la-Neuve 1348
32 1 047 58 11

IndustryMedical Devices
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Pierre MottetChairman of The Board55.93kN/A1962
Mr. Olivier LegrainCEO, President, MD & Executive Director937.52kN/A1968
Mr. Yves JongenFounder, Chief Research Officer, MD & Executive Director614.63kN/A1947
Ms. Soumya ChandramouliChief Financial OfficerN/AN/A1979
Mr. Frederic NolfChief Human Resources & Sustainability OfficerN/AN/A1973
Marc Van der BurghtChief Operation OfficerN/AN/AN/A
Olivier LechienCorporate Communication DirectorN/AN/AN/A
Thomas CanonSustainability Program DirectorN/AN/AN/A
Bruno ScutnairePresident of IBA RadioPharma SolutionsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Corporate governance

Ion Beam Applications SA’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder rights: 10; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.